Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)
ConditionGBS
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Ulm
About this trial
This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.
Eligibility criteria
Qualifiers
Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008)
age 18 years or above
Disqualifiers
Clinical or laboratory (C-reactive protein 20 mg/l or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection
Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment
Other contraindications against immunoadsorption or plasma exchange
Trial design
Treatments tested in this trial
- Immunoadsorption
- Plasma Exchange
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Ulm
Lead sponsor
DiaMed GmbH
Collaborator
Source ClinicalTrials.gov